Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Rüdiger Hehlmann, Michele Baccarani et al.|Blood|2011Cited by 497
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemiaRobin Foà, Antonella Vitale, Marco Vignetti et al.|Blood|2011Cited by 460
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Elias Jabbour, Andreas Hochhaus, Hagop M. Kantarjian et al.|Blood|2013Cited by 391
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Franck E. Nicolini et al.|Cancer Cell|2014Cited by 366
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibAndreas Hochhaus, H. Kantarjian, Michele Baccarani et al.|Leukemia|2008Cited by 354